Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.

Literature DB >> 35222503

Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.

Masatoshi Kudo¹.

Abstract

Entities: Chemical

Year: 2021 PMID： 35222503 PMCID： PMC8820154 DOI： 10.1159/000521374

Source DB: PubMed Journal: Liver Cancer ISSN： 1664-5553 Impact factor: 11.740

× No keyword cloud information.

14 in total

1. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

Authors: Philip J Johnson; Sarah Berhane; Chiaki Kagebayashi; Shinji Satomura; Mabel Teng; Helen L Reeves; James O'Beirne; Richard Fox; Anna Skowronska; Daniel Palmer; Winnie Yeo; Frankie Mo; Paul Lai; Mercedes Iñarrairaegui; Stephen L Chan; Bruno Sangro; Rebecca Miksad; Toshifumi Tada; Takashi Kumada; Hidenori Toyoda
Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544

2. Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade.

Authors: Takashi Kumada; Hidenori Toyoda; Toshifumi Tada; Satoshi Yasuda; Junko Tanaka
Journal: Liver Cancer Date: 2020-07-16 Impact factor: 11.740

Review 3. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.

Authors: Masatoshi Kudo; Yusuke Kawamura; Kiyoshi Hasegawa; Ryosuke Tateishi; Kazuya Kariyama; Shuichiro Shiina; Hidenori Toyoda; Yasuharu Imai; Atsushi Hiraoka; Masafumi Ikeda; Namiki Izumi; Michihisa Moriguchi; Sadahisa Ogasawara; Yasunori Minami; Kazuomi Ueshima; Takamichi Murakami; Shiro Miyayama; Osamu Nakashima; Hirohisa Yano; Michiie Sakamoto; Etsuro Hatano; Mitsuo Shimada; Norihiro Kokudo; Satoshi Mochida; Tetsuo Takehara
Journal: Liver Cancer Date: 2021-05-19 Impact factor: 11.740

4. Criteria for safe hepatic resection.

Authors: S Miyagawa; M Makuuchi; S Kawasaki; T Kakazu
Journal: Am J Surg Date: 1995-06 Impact factor: 2.565

5. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.

Authors: Atsushi Hiraoka; Takashi Kumada; Kunihiko Tsuji; Koichi Takaguchi; Ei Itobayashi; Kazuya Kariyama; Hironori Ochi; Kazuto Tajiri; Masashi Hirooka; Noritomo Shimada; Toru Ishikawa; Yoshihiko Tachi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
Journal: Liver Cancer Date: 2018-06-11 Impact factor: 11.740

6. EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.

Authors: Kazuya Kariyama; Kazuhiro Nouso; Atsushi Hiraoka; Akiko Wakuta; Ayano Oonishi; Teiji Kuzuya; Hidenori Toyoda; Toshifumi Tada; Kunihiko Tsuji; Ei Itobayashi; Toru Ishikawa; Koichi Takaguchi; Akemi Tsutsui; Noritomo Shimada; Masatoshi Kudo; Takashi Kumada
Journal: Liver Cancer Date: 2020-10-23 Impact factor: 11.740

7. Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.

Authors: Kazuomi Ueshima; Naoshi Nishida; Satoru Hagiwara; Tomoko Aoki; Tomohiro Minami; Hirokazu Chishina; Masahiro Takita; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Atsushi Hiraoka; Philip Johnson; Masatoshi Kudo
Journal: Cancers (Basel) Date: 2019-07-07 Impact factor: 6.639

8. Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.

Authors: Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Shinya Fukunishi; Hideko Ohama; Kazuhito Kawata; Joji Tani; Shinichiro Nakamura; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Tanaka Takaaki; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Kouji Joko; Yohei Koizumi; Yoichi Hiasa
Journal: Sci Rep Date: 2021-07-14 Impact factor: 4.379

3 in total

Review 1. Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis.

Authors: Gauri Mishra; Ammar Majeed; Anouk Dev; Guy D Eslick; David J Pinato; Hirofumi Izumoto; Atsushi Hiraoka; Teh-Ia Huo; Po-Hong Liu; Philip J Johnson; Stuart K Roberts
Journal: J Gastrointest Cancer Date: 2022-05-30

Review 2. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.

Authors: Masatoshi Kudo
Journal: Int J Clin Oncol Date: 2022-05-08 Impact factor: 3.850

3. Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response.

Authors: Yasunori Minami; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
Journal: Cancers (Basel) Date: 2022-10-04 Impact factor: 6.575

3 in total